Provider review
ARSYNL Rx review
Sells a needle-free spray alongside the injections, and prices both molecules identically.
Tirzepatide costs more to compound than semaglutide everywhere else here. The page does not explain the match.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
ARSYNL Rx
$233/month sema · $233/month tirz · $256.33/month spray
- Vs median
- $64/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Two things here are worth reading closely. The first is the spray. A needle-free delivery device is the rarest thing in this whole category and it addresses the practical problem at the center of holding a small dose: a quarter dose out of a syringe means trusting the markings on a barrel, and a metered device does not. It is the dearest of the three products by a modest margin, which is a reasonable premium for what it solves rather than the substantial one some sellers charge for a needle-free route. The second is the pricing of the two injectables, which is identical. Tirzepatide reliably costs more to compound than semaglutide, and across this site that gap runs from twenty to eighty dollars a month; here the two are the same figure to the dollar, and the page offers no explanation. That is not necessarily a problem — a seller may simply choose to price them level — but it is worth confirming at checkout rather than assuming, because a matching price on two drugs with different input costs usually means something is different about one of the products. All three figures are floors with no ceiling stated, and no milligram appears behind any of them.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want a needle-free option and would rather not draw a partial unit at all
- You want an explicit monthly term rather than a bare figure to budget from
- You want both molecules available from one seller at a predictable entry price
Look elsewhere if
- You need a ceiling. All three figures are floors
- You want the price difference between the two molecules explained. It is not
- You want a milligram behind the number. None of the three carries one
What it actually costs
Price as published
Three weight-loss products, each with an explicit monthly term: compounded semaglutide from $233.00/month, a tirzepatide with B12 line described as an advanced GLP-1 and GIP product from $233/month, and a Tirzepatide HypoSpray from $256.33/month · ★★ the HypoSpray is a needle-free delivery device rather than a syringe, which is a materially easier instrument for anyone drawing a deliberately small dose · the two injectable lines are priced IDENTICALLY at $233 despite one being a dual agonist — everywhere else on this site tirzepatide costs a seller more than semaglutide, so a matching price is unusual and the page does not explain it · every figure is a "from", so all three are floors with no ceiling published · both molecules are named, and the compounded status is stated · no dose is published behind any of the three
- Vs median
- $64/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. ★★ A NEEDLE-FREE SPRAY is sold alongside the injections and priced only modestly above them, which is the rarest thing in this category and addresses the practical problem at the center of holding a small dose: a quarter dose out of a syringe means trusting the markings on a barrel, and a metered device does not. All three products carry an explicit monthly term rather than a bare figure. The two injectables are priced IDENTICALLY despite one being a dual agonist, which is unusual — that gap runs twenty to eighty dollars elsewhere here — and the page does not explain it. Every figure is a floor with no ceiling and no dose behind it.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- A needle-free spray is sold alongside the injections, priced only modestly higher.
- All three products carry an explicit monthly term rather than a bare figure.
- Both molecules are named, with the compounded status stated.
Pharmacy, labs and oversight
ARSYNL Rx does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
2 of 4 published openly
What ARSYNL Rx publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
Two things here are worth reading closely. The first is the spray. A needle-free delivery device is the rarest thing in this whole category and it addresses the practical problem at the center of holding a small dose: a quarter dose out of a syringe means trusting the markings on a barrel, and a metered device does not. It is the dearest of the three products by a modest margin, which is a reasonable premium for what it solves rather than the substantial one some sellers charge for a needle-free route. The second is the pricing of the two injectables, which is identical. Tirzepatide reliably costs more to compound than semaglutide, and across this site that gap runs from twenty to eighty dollars a month; here the two are the same figure to the dollar, and the page offers no explanation. That is not necessarily a problem — a seller may simply choose to price them level — but it is the kind of detail worth confirming at checkout rather than assuming, because a matching price on two drugs with different input costs usually means something is different about one of the products. All three figures are floors with no ceiling stated, and no milligram appears behind any of them, so what quantity of drug the entry price buys is unstated as usual.
The honest cons
The two injectables are priced identically despite one being a dual agonist.
- Every figure is a floor with no ceiling published.
- No dose sits behind any of the three figures.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
ARSYNL Rx is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#268 of 373
Ordered with the companies that pay us first, and ARSYNL Rx is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Sublingual troches and drops
- Microdosing tirzepatide
- Microdose & reconstitution calculator
- The true annual cost of a plan
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.